Human beta-1,3-galactosyltransferase

Abstract

The present invention relates to polynucleotide and polypeptide molecules for znssp6, a novel member of the galactosyltransferase family. The polypeptides, and polynucleotides encoding them, are cell-cell interaction and glycoprotein synthesis modulating and may be used for delivery and therapeutics. The present invention also includes antibodies to the znssp6 polypeptides.

What is claimed is:  
     
         1 . An isolated polypeptide comprising residues 114 to 370 of SEQ ID NO: 2.  
     
     
         2 . The isolated polypeptide according to  claim 1  wherein the polypeptide comprises residues 114 to 378 of SEQ ID NO: 2.  
     
     
         3 . The isolated polypeptide according to  claim 2  wherein the polypeptide comprises residues 50 to 378 of SEQ ID NO: 2.  
     
     
         4 . The isolated polypeptide according to  claim 3  wherein the polypeptide comprises residues 26 to 378 of SEQ ID NO: 2.  
     
     
         5 . The isolated polypeptide according to  claim 4  wherein the polypeptide comprises residues 1 to 378 of SEQ ID NO: 2.  
     
     
         6 . An isolated polypeptide selected from the group consisting of: 
 a) a polypeptide comprising residues 1 to 25 of SEQ ID NO: 2;    b) a polypeptide comprising residues 26 to 49 of SEQ ID NO: 2;    c) a polypeptide comprising residues 50 to 113 of SEQ ID NO: 2;    d) a polypeptide comprising residues 114 to 370 of SEQ ID NO: 2;    e) a polypeptide comprising residues 371 to 378 of SEQ ID NO: 2; and    f) a polypeptide comprising residues 1 to 378 of SEQ ID NO: 2.    
     
     
         7 . An isolated polynucleotide encoding a polypeptide wherein the polypeptide comprises residues 114 to 370 of SEQ ID NO: 2.  
     
     
         8 . The isolated polynucleotide according to  claim 7 , wherein the polypeptide molecule comprises residues 114 to 378 of SEQ ID NO: 2.  
     
     
         9 . The isolated polynucleotide according to  claim 8 , wherein the polypeptide molecule comprises residues 50 to 378 of SEQ ID NO: 2.  
     
     
         10 . The isolated polynucleotide according to  claim 9 , wherein the polypeptide molecule comprises residues 26 to 378 of SEQ ID NO: 2.  
     
     
         11 . The isolated polynucleotide according to  claim 8 , wherein the polypeptide molecule comprises residues 1 to 378 of SEQ ID NO: 2.  
     
     
         12 . An isolated polynucleotide encoding a polypeptide molecule wherein the polypeptide is selected from the group consisting of: 
 a) a polypeptide comprising residues 1 to 25 of SEQ ID NO: 2;    b) a polypeptide comprising residues 26 to 49 of SEQ ID NO: 2;    c) a polypeptide comprising residues 50 to 113 of SEQ ID NO: 2;    d) a polypeptide comprising residues 114 to 370 of SEQ ID NO: 2;    e) a polypeptide comprising residues 371 to 378 of SEQ ID NO: 2; and    f) a polypeptide comprising residues 1 to 378 of SEQ ID NO: 2.    
     
     
         13 . An expression vector comprising the following operably linked elements: 
 a transcription promoter;    a DNA segment wherein the DNA segment is a polynucleotide encoding the polypeptide of  claim 1;  and    a transcription terminator.    
     
     
         14 . The expression vector according to  claim 13  wherein the DNA segment contains an affinity tag.  
     
     
         15 . A cultured cell into which has been introduced an expression vector according to  claim 13 , wherein said cell expresses the polypeptide encoded by the DNA segment.  
     
     
         16 . A method of producing a polypeptide comprising culturing a cell according to  claim 15 , whereby said cell expresses the polypeptide encoded by the DNA segment; and recovering the polypeptide.  
     
     
         17 . The polypeptide produced by the method of  claim 16 .  
     
     
         18 . A method of producing an antibody comprising the following steps in order: 
 inoculating an animal with an epitope bearing portion of a polypeptide wherein the epitope bearing portion is selected from the group consisting of: 
 a) a polypeptide comprising residues 10 to 16 of SEQ ID NO: 2;  
 b) a polypeptide comprising residues 52 to 61 of SEQ ID NO: 2;  
 c) a polypeptide comprising residues 52 to 78 of SEQ ID NO: 2;  
 d) a polypeptide comprising residues 69 to 78 of SEQ ID NO: 2;  
 e) a polypeptide comprising residues 89 to 94 of SEQ ID NO: 2;  
 f) a polypeptide comprising residues 89 to 117 of SEQ ID NO: 2;  
 g) a polypeptide comprising residues 111 to 117 of SEQ ID NO: 2;  
 h) a polypeptide comprising residues 126 to 134 of SEQ ID NO: 2;  
 i) a polypeptide comprising residues 126 to 151 of SEQ ID NO: 2;  
 j) a polypeptide comprising residues 143 to 151 of SEQ ID NO: 2;  
 k) a polypeptide comprising residues 215 to 220 of SEQ ID NO: 2;  
 l) a polypeptide comprising residues 215 to 239 of SEQ ID NO: 2;  
 m) a polypeptide comprising residues 223 to 239 of SEQ ID NO: 2;  
 n) a polypeptide comprising residues 223 to 257 of SEQ ID NO: 2;  
 o) a polypeptide comprising residues 251 to 257 of SEQ ID NO: 2; and  
 p) a polypeptide comprising residues 332 to 337 of SEQ ID NO: 2  
   wherein the polypeptide elicits an immune response in the animal to produce the antibody; and isolating the antibody from the animal.    
     
     
         19 . An antibody produced by the method of  claim 18 , which binds to a polypeptide comprising residues 114 to 370 of SEQ ID NO: 2.  
     
     
         20 . The antibody of  claim 19 , wherein the antibody is a monoclonal antibody.  
     
     
         21 . The antibody of  claim 19  joined to a moiety selected from the group consisting of: 
 a) an affinity tag;  
 b) a detectable molecule;  
 c) a cytotoxic molecule; and  
 d) a cytokine.  
 
     
     
         22 . A method of killing cells expressing a polypeptide comprising residues 114 to 370 of SEQ ID NO: 2, comprising contacting the cells with the antibody of  claim 21 , wherein the antibody is joined to the cytotoxic molecule.  
     
     
         23 . A method of modulating cell-cell interactions comprising contacting the cells with polypeptide of  claim 1 .  
     
     
         24 . A method for modulating cell-cell interactions according to  claim 23 , wherein the cells are derived from tissues selected from the group consisting of: 
 a) tissues from brain;    b) tissues from kidney; and    c) tissues from testis.    
     
     
         25 . A method for modulating glycoprotein and glycolipid biosynthesis in cells, cell matrix, or cell culture comprising contacting the cells, cell culutre, or cell matrix with the polypeptide of  claim 1 .  
     
     
         26 . A method for modulating glycoprotein and glycolipid biosynthesis according to  claim 25 , wherein the cells, cell culture or cell matrix are derived from tissues selected from the group consisting of: 
 a) tissues from brain;    b) tissues from kidney; and    c) tissues from testis.    
     
     
         27 . A method of detecting a znssp6 anti-complementary molecule comprising contacting a test sample containing the znssp6 anti-complementary molecule with the polypeptide of  claim 1.